





Project StAR-2

StAR National Antimicrobial Stewardship Programs: 3rd SwissASP Networking Zoom call, 26 May 2021, 9-10h30 *Meeting summary report*

1. Summary

This report presents key discussion points in the interactive 3rd SwissASP Networking Zoom call on 26 March 2021. The call focused on local quality improvement (QI) efforts and how they can be used for antibiotic stewardship programming (ASP; including local experience from two hospitals) before the planned face-to-face meeting in August.

2. Background and meeting purpose

The SwissASP working documents (framework conditions and portfolio) were developed during the first project phase of the FOPH-funded national Strategy against Antibiotic Resistance in the human sector (StAR-1) to provide evidence-based recommendations on the successful implementation of ASP in hospitals in Switzerland. The StAR-2 phase aims to create a functioning network for the development and implementation of bottom-up ASP activities and sharing stewardship tools and experiences.

The first SwissASP networking Zoom call in November 2020 focused on experiences in stewardship implementation in different local settings, the 2nd networking call on the use of quality improvement audits, potential challenges and barriers in adherence to prescription guidelines, and ideas on how to move forward with ASP implementation.

3. Audience

Invitees included all hospital contacts of Swissnoso and link hospital pharmacists of the Anresis network. The calls had about 50 participants from acute care hospitals (pharmacists and senior physicians, infectious diseases, IPC, and internal medicine) either involved or interested in getting involved in antibiotic stewardship.


- 4. Meeting format, content/speakers (Agenda→Annex) and critical discussion points
- a) First part of the meeting







JB welcomed the participants to the call focusing on the use of data, data sharing/QI, and presented current priorities of the SwissASP project, as illustrated in the following chart.



JB further informed about the proposed SwissASP working/meeting in August with international guest speakers on stewardship (SwissASP meeting on Wed, 25 August 2021. Either face-to-face in Bern or virtual via Zoom). Educational and interactive workshop activities in smaller groups (escape room style) are planned.

b) Second part of the meeting

Presentations with Q&A (second part) on data sharing, QI, and experiences in initiating AS with existing local resources. See presentation slides \rightarrow see Annex and separate PDF file. In addition, there will be more information on data analysis and data sharing for ASP in the following network interaction. Starting local ASP using the resources already available will be the subject of the upcoming SwissASP workshop event.

5. Next steps

Please save the date: SwissASP workshop, Wed, 25 Aug 2021, face-to-face in Bern or virtual

6. References

SwissASP Portfolio Version 2/31 Oct 2019 SwissASP framework conditions V2/27 Oct 2019







7. Annex

I. Agenda

| Time | Subject | Speaker |
|-------|--|--------------------------------------|
| #8:45 | Call opening | |
| 09:00 | Welcome and introduction | Dr. Julia Bielicki UKBB/Swissnoso |
| 09:05 | recap and next priorities for SwissASP | Dr. Julia Bielicki UKBB/Swissnoso |
| 09:20 | Presentation: Presenting data: What, When, How? (Julia Bielicki, UKBB) | Dr. Julia Bielicki UKBB/Swissnoso |
| 09:35 | Presentation: Summary of REDcap feedback: Local leads' experiences in QI audit | Dr. Marcus Eder Swissnoso |
| 09.45 | Presentation: Work in progress Experience with digital antibiotic stewardship surveillance | - Dr. Benedikt Wiggli, SP Baden |
| 10:30 | Presentation: Starting off local stewardship | Dr. Yvonne Schmiedel, SP Delémont |
| 10:55 | Wrap up of Meeting | Dr. Julia Bielicki UKBB/Swissnoso |
| 11:00 | End of meeting | |

II. Presentations (see separate PDF file)

- Presenting data: What, When, How? (Julia Bielicki, UKBB)
- Work in progress: Experience with digital antibiotic stewardship surveillance (Benedikt Wiggli, SP Baden)
- Work in progress: Starting local stewardship (Yvonne Schmiedel, SP Delémont)



National Center for Infection Control

Swissasp

Presenting data: What, When, How?

Dr. med. Julia Bielicki, PhD MPH

Why are (local) data important to AS?

- To know what your baseline is
- To measure change over time
- To identify opportunities for interventions
- To define determinants of practice
- To allocate resources
- To benchmark against others



What is audit and feedback?

Tracking of practices with direct reporting back (with or without comparison of performance to peers)

Goal

Increase awareness of practices and highlight divergence from guidelines or peers

Impact

Helps identify outliers and drive behaviour change


Supplemental action


Can be personalised in writing or through educational detailing

Caveats

• Not durable – once stopped, return to pre-intervention levels expected








Van Limburg et al. ARIC. 2014;


| Code | Sub-code | Variation | n | Quote |
|-------------------|-----------|---|----|---|
| Needs audit | Content | Insights in diagnostics | 6 | "Do we use the right diagnostics for our patients? In other words, do we test too much or do we take the wrong tests?" P(17.36) |
| | | Insights in empirical and targeted treatment | 4 | "I would like to know for a certain clinical presentation how we start our treatment, which antibiotics we start with." P(13.29) |
| | | Insights in infection control measures | 4 | "For infection control I would like to know what percentage gets clean clothes every day. And what effect that would have on the prevention of new infections. I would also like to know if hand hygiene is adequately applied and if people comply to the dress code. Also, the use of non-sterile or sterile gloves." R(04.16) |
| | | Insights in infection outcomes | 3 | "I would like to see how we perform in the hospital; how often do we have resistant micro-organisms and how often are these transmitted to other patients or personnel." R(05.21) |
| | | Insights in resistance patterns | 5 | "Insights in diagnostic results, resistance patterns, not for individual patients, but overall. How the resistance patterns have developed over time." P(02.16) |
| | Norms | Benchmark | 8 | "If I would be compared to colleagues for example, that might be scary, but eventually you can learn a lot from it." R(04.31) |
| | | Trends over time | 4 | "You could do a baseline measurement, so how are we performing now. And then look how it evolves over time when you change things." P(17.50) |
| Needs feedback | Content | Simple and concrete points of improvement and recommendations | 7 | "Some points we might be able to change ourselves, such as poor hygiene or so. But it may also be that policies need to be adapted, that certain antibiotics may or may not be given anymore. You really have to give something back that it is not just plain facts." N(09.56) |
| | | Feedback tailored to target group | 8 | "I would indeed stick to one group [nurses or physicians] and focus on that specific target group. Adapt the feedback to that group." N(15.23) |
| | | Substantiated recommendations | 11 | "I want to be convinced with good arguments. I understand that there are rules and you must adhere to them, so I adhere to them. But I find it very annoying when people can't explain why. It seems logical and it is tangible, but if it is not scientifically proven, then I think you should thoroughly study it before you set a rule." P(08.33) |
| | Form | Mail/ newsletter /poster | 4 | "I would like to receive some kind of newsletter online". P(05.31) |
| | | Interactive | 13 | "Just data is an empty shell. You have to present it, you have to discuss it, you have to work with it." R(04.40) |
| | Frequency | Not too often, but recurrent | 14 | "Oh, not every week or month, then it is way too much. I think every six months, something like that. Because otherwise it will only overwhelm you and then it seems to be a goal and not a means for something." P(17.62) |
| AF | Approach | Positive | 4 | "I think positive reinforcement is better than focusing on the negative." P(14.40) |
| implementation | | Transparent | 1 | "If there are consequences from AF, you have to explain in advance clearly why it happens with what purpose, that it is linked to a standard and that there is time to improve." P(17.62) |
| | Ownership | Bottom-up | 9 | "It is also easier to hear feedback from someone you see more often than from someone who just shows up and has something to say about your work." N(15.43) |
| | | AMR/infection experts | 8 | "By someone who is knowledgeable about these topics." N(09.49) |
| | | Interdisciplinary | 6 | "It would be very valuable to have regularly multidisciplinary meeting with the bacteriologists and possibly infectiologists or an infection committee." P(02.24) |
| | | Supported by supervisors and management | 3 | "It must be supported by the organization, so people at the top, the management." R(10.44) |

 ${\cal P}$ physician, ${\cal R}$ resident, ${\cal N}$ nurse

Keizer et al. ARIC. 2020;







Gerber et al. JAMA. 2013; Gerber et al. JAMA. 2014;



Syndrome-specific tracking and interventions

What is syndrome-specific tracking?

Tracking of practices for one or more syndromes

Goal

• Improve prescribing practices for conditions with known high levels of inappropriate prescribing

Impact


Implementation and tracking of interventions for conditions with clear prescribing guidelines


Caveats


- Needs to be a high-burden syndrome
- When guidelines are unavailable this becomes less suitable




Syndrome-specific tracking and interventions











Haas et al. Open Forum Infect Dis. 2016;



Combining Syndrome-specific interventions with Audit and Feedback







What is benchmarking?

Comparison to internal or external standards

Goal

Identify deviations from the expected

<u>Impact</u>

Helps identify outliers, target interventions, track over time

Risk adjustment


Important for meaningful comparisons to control for differences

Caveats

- Cannot identify inappropriate prescribing (ecological fallacy)
- Does not reflect diagnostics (generally speaking)

Dellit et al. Clin Infect Dis. 2007; Polk et al. Clin Infect Dis. 2011; Fridkin et al. Clin Infect Dis. 2014;







Meeker et al. JAMA, 2016;

Point prevalence surveillance – looking at local data

| | PP | PPS2 | |
|-------------------------------|---------------|------------|---------------|
| Measure | Your hospital | National | Your hospital |
| N patients surveyed | 325 | 12931 | 294 |
| N (%) on antimicrobials | 104 (32%) | 4267 (33%) | 94 (32%) |
| N (%) on single antimicrobial | 79 (76%) | 3516 (82%) | 77 (82%) |
| | | | |
| N (%) prescriptions | 133 | 8636 | 113 |
| - for parenteral antibiotics | 69 (52%) | 5268 (61%) | 51 (45%) 🕥 🛰 |
| - with indication recorded | 106 (80%) | 6736 (78%) | 88 (78%) 🔄 🛰 |
| - compliant with local policy | 110 (83%) | 7168 (83%) | 94 (83%) |
| | | | |
| N (%) surgical prophylaxis | 28 | 1554 | 23 |
| - single dose | 14 (50%) | 357 (23%) | 15 (65%) 🕑 🚾 |
| - 24 hours | 3 (12%) | 497 (32%) | 4 (17%) |
| ->24 hours | 11 (38%) | 699 (45%) | 4 (17%) 🕒 🛰 |








Ibrahim and Polk. Infectious Disease Clinics. 2014;





Ibrahim and Polk. Infectious Disease Clinics. 2014;



Conclusions

- Know your audience
- Recognise that data may relate to an individual (prescriber or patient) or to a population (prescriber or patient)
- Experiment with different visualisations and tables
- Talk to your prescribers what do they want and need?
- Think PDSA data drives the S part
- Set a compliance threshold rather than more complex targets
- Small sample size \rightarrow motivation: yes, comparison: no
- Beware of case-mix and use of non-comparable metrics in benchmarking

